March 28, 2025
At Friends of Cancer Research, we have long been committed to increasing efficiency in the development of new medicines through advancing groundbreaking science and innovative policy. The recent announcement that 3,500 FDA staff will be let go underscores just how serious and immediate the consequences of these cuts have become. Alongside broader reductions at NIH…
Read MoreMarch 3, 2025
Friends of Cancer Research (Friends) is honored to announce the addition of former Director of the National Institutes of Health (NIH) Dr. Monica Bertagnolli, to its Board of Directors. “Dr. Bertagnolli has built her incredible career around improving the lives of patients through advancing science and public health and increased access to care,” said Friends’ Chair & Founder, Ellen…
Read MoreFebruary 12, 2025
At Friends of Cancer Research, we have long been committed to increasing efficiency in the development of new medicines through advancing groundbreaking science and innovative policy. Drastic cuts to the workforce at the FDA, NIH, and other key health agencies threaten to undermine the very foundation of American scientific leadership, innovation, and public health. These agencies are…
Read MoreJanuary 21, 2025
Washington, DC – Friends of Cancer Research (Friends) is excited to announce the addition of Dr. Janet Woodcock, Former Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA) and Paul Kim, Principal of Kendall Square Policy Strategies LLC, to its Board of Directors. Dr. Janet Woodcock…
Read MoreDecember 12, 2024
Washington, DC – New findings by Friends of Cancer Research (Friends) and collaborators were presented yesterday at the San Antonio Breast Cancer Symposium (SABCS), “Agreement Across 10 Artificial Intelligence Models in Assessing HER2 in Breast Cancer Whole Slide Images: Findings from the Friends of Cancer Research Digital PATH Project.” The poster presented the agreement of…
Read MoreNovember 4, 2024
Six organizations representing millions of patients and providers, filed an amicus curiae, or “friend-of-the-court,” brief in the case of American Clinical Laboratory Association et al v. U.S. Food and Drug Administration (FDA) in the U.S. District Court in the Eastern District of Texas. The amicus brief supports the FDA’s laboratory developed tests (LDTs) rule that harmonized oversight for diagnostic tests regardless of whether…
Read MoreNovember 4, 2024
Findings by Friends of Cancer Research (Friends) and collaborators were published today in JCO Oncology Advances, “An Analysis of 20 Independently Performed Assays to Measure Homologous Recombination Deficiency (HRD) in Ovarian Cancer: Findings from the Friends’ HRD Harmonization Project.” This manuscript examines variability in outputs from HRD assays assessing a common sample set. HRD is a biomarker used to determine eligibility for Poly ADP-ribose Polymerase Inhibitors (PARPi) to treat patients with high-grade serous ovarian carcinoma…
Read MoreAugust 19, 2024
New findings by Friends of Cancer Research (Friends) were published recently in JCO Clinical Cancer Informatics “Evaluation of real-world tumor response derived from electronic health record data sources: A feasibility analysis in mNSCLC patients treated with chemotherapy.” This salient publication demonstrates the feasibility of aligning disparate real-world (rw) data sources to evaluate rw-response to treatment…
Read MoreJuly 18, 2024
Friends of Cancer Research (Friends) is proud to announce our 2024 Cancer Leadership Award recipients: Director of the National Institutes of Health, Dr. Monica Bertagnolli, and U.S. Representative for Kentucky’s 2nd congressional district, the Honorable Brett Guthrie. These two extraordinary leaders will be honored on September 19, 2024, in Washington, DC. Dr. Monica Bertagnolli will…
Read MoreJune 17, 2024
A new publication by Friends of Cancer Research (Friends) was published in Clinical Cancer Research, a journal of the American Association for Cancer Research, “An evaluation of novel oncology approvals with a PMR/C for assessing data in racial and ethnic populations underrepresented in premarket clinical trials.” This important publication used publicly available data to…
Read More
